1. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications
- Author
-
Hong Lin, Motoo Nagane, Webster K. Cavenee, and H.-J. Su Huang
- Subjects
Cancer Research ,Apoptosis ,Glioma ,Biology ,Tyrphostins ,medicine.disease ,medicine.disease_cause ,ErbB Receptors ,Oncology ,Growth factor receptor ,Epidermal growth factor ,Tumor progression ,Drug Resistance, Neoplasm ,Mutation ,medicine ,Cancer research ,biology.protein ,Quinazolines ,Humans ,Epidermal growth factor receptor ,Signal transduction ,Carcinogenesis ,Tyrosine kinase ,Signal Transduction - Abstract
Alterations of the epidermal growth factor receptor (EGFR) occur frequently in malignant gliomas through gene amplification or rearrangement, especially in a large fraction of de novo type glioblastomas. The most common of these mutant EGFRs (variously named de2-7 EGFR, deltaEGFR or EGFRvIII) lacks a portion of the extracellular ligand-binding domain. Here, we review the evidence that shows that expression of deltaEGFR bestows in vivo growth advantages to human glioma cells through its constitutively active tyrosine kinase activity. Thus, deltaEGFR may provide a novel therapeutic target for the most aggressive type of glioblastoma.
- Published
- 2001